Galapagos NV (NASDAQ:GLPG)
| 55.58 Delayed Data As of 3:59pm ET |  -0.37 / -0.66%Today’s Change | 46.41 Today|||52-Week Range 72.11 | +0.82% Year-to-Date |
Latest GLPG News | Press Releases
| Are Medical Stocks Lagging Galapagos (GLPG) This Year? 9:40am / Zacks.com - Paid Partner Content | Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA Jun 16 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 55.95 |
| Today’s open | 55.27 |
| Day’s range | 55.01 - 55.90 |
| Volume | 6,830 |
| Average volume (3 months) | 298,648 |
| Market cap | $3.7B |
Data as of 3:59pm ET, 06/29/2022
Growth & Valuation
| Earnings growth (last year) | +57.70% |
| Earnings growth (this year) | +7.26% |
| Earnings growth (next 5 years) | -12.57% |
| Revenue growth (last year) | +5.16% |
| P/E ratio | NM |
| Price/Sales | 6.30 |
| Price/Book | 1.22 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TPTXTurning Point Therap... | +0.21 | +0.28% |
| KRTXKaruna Therapeutics ... | +4.12 | +3.41% |
| MRTXMirati Therapeutics ... | -1.26 | -1.84% |
| ---- |
Data as of 4:00pm ET, 06/29/2022
Financials
| Next reporting date | August 4, 2022 |
| EPS forecast (this quarter) | -$0.74 |
| Annual revenue (last year) | $573.1M |
| Annual profit (last year) | -$148.2M |
| Net profit margin | -25.87% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Mechelen, Brussels Region |
Forecasts
